To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:10c1c6d6cac9bc8f6863461901374594]
Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:10c1c6d6cac9bc8f6863461901374594]
Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
Bio2RDF identifier
10c1c6d6cac9bc8f6863461901374594
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:10c1c6d6cac9bc8f6863461901374594
measure [clinicaltrials_vocabulary:measure]
To compare fosaprepitant dimeg ...... concomitant weekly cisplatin.
time frame [clinicaltrials_vocabulary:time-frame]
description
Addition of fosaprepitant dime ...... examethasone and palonosetron.
identifier
clinicaltrials_resource:10c1c6d6cac9bc8f6863461901374594
title
To compare fosaprepitant dimeg ...... tant weekly cisplatin. 35 days
@en
type
label
To compare fosaprepitant dimeg ...... 1c6d6cac9bc8f6863461901374594]
@en